Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Liabilities and Shareholders Equity (2016 - 2025)

UroGen Pharma (URGN) has disclosed Liabilities and Shareholders Equity for 10 consecutive years, with $200.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 29.84% year-over-year to $200.5 million, compared with a TTM value of $841.8 million through Dec 2025, down 21.33%, and an annual FY2025 reading of $200.5 million, down 29.84% over the prior year.
  • Liabilities and Shareholders Equity was $200.5 million for Q4 2025 at UroGen Pharma, up from $185.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $301.9 million in Q3 2024 and bottomed at $95.4 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $178.7 million, with a median of $172.0 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity crashed 41.64% in 2021, then soared 195.56% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $119.7 million in 2021, then grew by 13.26% to $135.6 million in 2022, then surged by 31.48% to $178.3 million in 2023, then skyrocketed by 60.23% to $285.7 million in 2024, then decreased by 29.84% to $200.5 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for URGN at $200.5 million in Q4 2025, $185.0 million in Q3 2025, and $208.7 million in Q2 2025.